ID   ACK1_HUMAN              Reviewed;        1038 AA.
AC   Q07912; Q6ZMQ0; Q8N6U7; Q96H59;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   12-OCT-2022, entry version 224.
DE   RecName: Full=Activated CDC42 kinase 1;
DE            Short=ACK-1;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:20333297};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068};
DE   AltName: Full=Tyrosine kinase non-receptor protein 2;
GN   Name=TNK2; Synonyms=ACK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDC42.
RC   TISSUE=Hippocampus;
RX   PubMed=8497321; DOI=10.1038/363364a0;
RA   Manser E., Leung T., Salihuddin H., Tan L., Lim L.;
RT   "A non-receptor tyrosine kinase that inhibits the GTPase activity of
RT   p21cdc42.";
RL   Nature 363:364-367(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-725.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH CSPG4.
RX   PubMed=10587647; DOI=10.1038/70302;
RA   Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.-L.,
RA   Tachibana K., Lim L., Manser E., Furcht L.T., Iida J.;
RT   "Melanoma chondroitin sulphate proteoglycan regulates cell spreading
RT   through Cdc42, Ack-1 and p130cas.";
RL   Nat. Cell Biol. 1:507-513(1999).
RN   [6]
RP   FUNCTION AS MCF2 KINASE, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=10652228; DOI=10.1006/bbrc.2000.2106;
RA   Kato J., Kaziro Y., Satoh T.;
RT   "Activation of the guanine nucleotide exchange factor Dbl following ACK1-
RT   dependent tyrosine phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 268:141-147(2000).
RN   [7]
RP   FUNCTION.
RX   PubMed=11278436; DOI=10.1074/jbc.m008795200;
RA   Teo M., Tan L., Lim L., Manser E.;
RT   "The tyrosine kinase ACK1 associates with clathrin-coated vesicles through
RT   a binding motif shared by arrestin and other adaptors.";
RL   J. Biol. Chem. 276:18392-18398(2001).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14733946; DOI=10.1016/j.bbrc.2003.12.137;
RA   Ahmed I., Calle Y., Sayed M.A., Kamal J.M., Rengaswamy P., Manser E.,
RA   Meiners S., Nur-E-Kamal A.;
RT   "Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase,
RT   ACK.";
RL   Biochem. Biophys. Res. Commun. 314:571-579(2004).
RN   [9]
RP   AUTOPHOSPHORYLATION, INTERACTION WITH HSP90AB1; MTERK AND WWOX, AND
RP   MUTAGENESIS OF LYS-158 AND LEU-487.
RX   PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127;
RA   Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.;
RT   "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of
RT   Ack1 in polyubiquitination of tumor suppressor Wwox.";
RL   Cancer Res. 65:10514-10523(2005).
RN   [10]
RP   INTERACTION WITH SNX9, AND SUBCELLULAR LOCATION.
RX   PubMed=16137687; DOI=10.1016/j.febslet.2005.07.093;
RA   Yeow-Fong L., Lim L., Manser E.;
RT   "SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector
RT   ACK1.";
RL   FEBS Lett. 579:5040-5048(2005).
RN   [11]
RP   FUNCTION AS WAS KINASE, INTERACTION WITH WASL, CATALYTIC ACTIVITY, AND
RP   COFACTOR.
RX   PubMed=16257963; DOI=10.1074/jbc.m506996200;
RA   Yokoyama N., Lougheed J., Miller W.T.;
RT   "Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual
RT   hydroxyamino acid specificity in a tyrosine kinase.";
RL   J. Biol. Chem. 280:42219-42226(2005).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [13]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16247015; DOI=10.1073/pnas.0508014102;
RA   van der Horst E.H., Degenhardt Y.Y., Strelow A., Slavin A., Chinn L.,
RA   Orf J., Rong M., Li S., See L.-H., Nguyen K.Q.C., Hoey T., Wesche H.,
RA   Powers S.;
RT   "Metastatic properties and genomic amplification of the tyrosine kinase
RT   gene ACK1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15901-15906(2005).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   FUNCTION IN CELL MIGRATION, AND INTERACTION WITH BCAR1; CDC42 AND CRK.
RX   PubMed=17038317; DOI=10.1074/jbc.m604342200;
RA   Modzelewska K., Newman L.P., Desai R., Keely P.J.;
RT   "Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas.";
RL   J. Biol. Chem. 281:37527-37535(2006).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT TYR-284.
RX   PubMed=16472662; DOI=10.1016/s0076-6879(06)06018-6;
RA   Yokoyama N., Miller W.T.;
RT   "Purification and enzyme activity of ACK1.";
RL   Methods Enzymol. 406:250-260(2006).
RN   [17]
RP   INTERACTION WITH AR.
RX   PubMed=17494760; DOI=10.1073/pnas.0700420104;
RA   Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L.,
RA   Earp H.S., Whang Y.E.;
RT   "Activated Cdc42-associated kinase Ack1 promotes prostate cancer
RT   progression via androgen receptor tyrosine phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007).
RN   [18]
RP   INTERACTION WITH NPHP1.
RX   PubMed=18477472; DOI=10.1016/j.bbrc.2008.05.016;
RA   Eley L., Moochhala S.H., Simms R., Hildebrandt F., Sayer J.A.;
RT   "Nephrocystin-1 interacts directly with Ack1 and is expressed in human
RT   collecting duct.";
RL   Biochem. Biophys. Res. Commun. 371:877-882(2008).
RN   [19]
RP   FUNCTION.
RX   PubMed=18435854; DOI=10.1186/bcr2087;
RA   Howlin J., Rosenkvist J., Andersson T.;
RT   "TNK2 preserves epidermal growth factor receptor expression on the cell
RT   surface and enhances migration and invasion of human breast cancer cells.";
RL   Breast Cancer Res. 10:R36-R36(2008).
RN   [20]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18262180; DOI=10.1016/j.yexcr.2007.12.017;
RA   Groevdal L.M., Johannessen L.E., Roedland M.S., Madshus I.H., Stang E.;
RT   "Dysregulation of Ack1 inhibits down-regulation of the EGF receptor.";
RL   Exp. Cell Res. 314:1292-1300(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-881, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   INTERACTION WITH NEDD4, AND UBIQUITINATION.
RX   PubMed=19144635; DOI=10.1074/jbc.m806877200;
RA   Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E.;
RT   "Down-regulation of active ACK1 is mediated by association with the E3
RT   ubiquitin ligase Nedd4-2.";
RL   J. Biol. Chem. 284:8185-8194(2009).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH AXL; LTK; PDGFRL AND GRB2.
RX   PubMed=19815557; DOI=10.1074/jbc.m109.072660;
RA   Pao-Chun L., Chan P.M., Chan W., Manser E.;
RT   "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is
RT   mediated by Grb2: an analysis of ACK1 effects on Axl signaling.";
RL   J. Biol. Chem. 284:34954-34963(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-284 AND SER-724, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-284, AND DOMAIN
RP   SAM-LIKE.
RX   PubMed=20979614; DOI=10.1186/1471-2091-11-42;
RA   Prieto-Echaguee V., Gucwa A., Brown D.A., Miller W.T.;
RT   "Regulation of Ack1 localization and activity by the amino-terminal SAM
RT   domain.";
RL   BMC Biochem. 11:42-42(2010).
RN   [27]
RP   FUNCTION, SUBCELLULAR LOCATION, VARIANTS LEU-34; GLN-99; LYS-346 AND
RP   ILE-409, CHARACTERIZATION OF VARIANTS LEU-34; GLN-99; LYS-346 AND ILE-409,
RP   AND MUTAGENESIS OF LEU-120; LEU-197 AND VAL-365.
RX   PubMed=20110370; DOI=10.1074/jbc.m109.060459;
RA   Prieto-Echaguee V., Gucwa A., Craddock B.P., Brown D.A., Miller W.T.;
RT   "Cancer-associated mutations activate the nonreceptor tyrosine kinase
RT   Ack1.";
RL   J. Biol. Chem. 285:10605-10615(2010).
RN   [28]
RP   FUNCTION AS AR KINASE, AND ACTIVITY REGULATION.
RX   PubMed=20383201; DOI=10.1038/onc.2010.103;
RA   Liu Y., Karaca M., Zhang Z., Gioeli D., Earp H.S., Whang Y.E.;
RT   "Dasatinib inhibits site-specific tyrosine phosphorylation of androgen
RT   receptor by Ack1 and Src kinases.";
RL   Oncogene 29:3208-3216(2010).
RN   [29]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH AKT1, SUBCELLULAR
RP   LOCATION, CHARACTERIZATION OF VARIANT LYS-346, PHOSPHORYLATION AT TYR-284,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=20333297; DOI=10.1371/journal.pone.0009646;
RA   Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S.,
RA   Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q.,
RA   Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.;
RT   "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its
RT   activation.";
RL   PLoS ONE 5:E9646-E9646(2010).
RN   [30]
RP   PHOSPHORYLATION AT TYR-284, TISSUE SPECIFICITY, AND ACTIVITY REGULATION.
RX   PubMed=20623637; DOI=10.1002/pros.21163;
RA   Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H.,
RA   Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.;
RT   "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen
RT   receptor activity.";
RL   Prostate 70:1274-1285(2010).
RN   [31]
RP   PHOSPHORYLATION AT TYR-284, AND INTERACTION WITH SRC.
RX   PubMed=21309750; DOI=10.1042/bj20102156;
RA   Chan W., Sit S.T., Manser E.;
RT   "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires Src
RT   for activation.";
RL   Biochem. J. 435:355-364(2011).
RN   [32]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284; TYR-518; TYR-827;
RP   TYR-859 AND TYR-872.
RX   PubMed=21169560; DOI=10.1091/mbc.e10-07-0637;
RA   Shen H., Ferguson S.M., Dephoure N., Park R., Yang Y., Volpicelli-Daley L.,
RA   Gygi S., Schlessinger J., De Camilli P.;
RT   "Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at
RT   arrested endocytic clathrin-coated pits of cells that lack dynamin.";
RL   Mol. Biol. Cell 22:493-502(2011).
RN   [33]
RP   REVIEW ON TUMOR GROWTH.
RX   PubMed=20432460; DOI=10.1002/jcp.22162;
RA   Mahajan K., Mahajan N.P.;
RT   "Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.";
RL   J. Cell. Physiol. 224:327-333(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   STRUCTURE BY NMR OF 448-489.
RX   PubMed=10360579; DOI=10.1038/20732;
RA   Mott H.R., Owen D., Nietlispach D., Lowe P.N., Manser E., Lim L.,
RA   Laue E.D.;
RT   "Structure of the small G protein Cdc42 bound to the GTPase-binding domain
RT   of ACK.";
RL   Nature 399:384-388(1999).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 107-395, AND PHOSPHORYLATION AT
RP   TYR-284.
RX   PubMed=15308621; DOI=10.1074/jbc.m406703200;
RA   Lougheed J.C., Chen R.-H., Mak P., Stout T.J.;
RT   "Crystal structures of the phosphorylated and unphosphorylated kinase
RT   domains of the Cdc42-associated tyrosine kinase ACK1.";
RL   J. Biol. Chem. 279:44039-44045(2004).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 117-392 IN COMPLEX WITH INHIBITOR,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=18993068; DOI=10.1016/j.bmcl.2008.10.092;
RA   Kopecky D.J., Hao X., Chen Y., Fu J., Jiao X., Jaen J.C., Cardozo M.G.,
RA   Liu J., Wang Z., Walker N.P., Wesche H., Li S., Farrelly E., Xiao S.H.,
RA   Kayser F.;
RT   "Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-
RT   d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 18:6352-6356(2008).
RN   [38]
RP   VARIANTS LEU-34; ARG-71; GLN-99; TRP-99; MET-152; LYS-346; ILE-409;
RP   SER-507; LEU-725; GLN-748 AND HIS-1038.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [39]
RP   VARIANT MET-638, INTERACTION WITH NEDD4 AND NEDD4L, AND CHARACTERIZATION OF
RP   VARIANT MET-638.
RX   PubMed=23686771; DOI=10.1002/ana.23934;
RA   Hitomi Y., Heinzen E.L., Donatello S., Dahl H.H., Damiano J.A.,
RA   McMahon J.M., Berkovic S.F., Scheffer I.E., Legros B., Rai M.,
RA   Weckhuysen S., Suls A., De Jonghe P., Pandolfo M., Goldstein D.B.,
RA   Van Bogaert P., Depondt C.;
RT   "Mutations in TNK2 in severe autosomal recessive infantile onset
RT   epilepsy.";
RL   Ann. Neurol. 74:496-501(2013).
CC   -!- FUNCTION: Non-receptor tyrosine-protein and serine/threonine-protein
CC       kinase that is implicated in cell spreading and migration, cell
CC       survival, cell growth and proliferation. Transduces extracellular
CC       signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR,
CC       MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated
CC       endocytosis through binding to epidermal growth factor receptor (EGFR)
CC       and clathrin. Binds to both poly- and mono-ubiquitin and regulates
CC       ligand-induced degradation of EGFR, thereby contributing to the
CC       accumulation of EGFR at the limiting membrane of early endosomes.
CC       Downstream effector of CDC42 which mediates CDC42-dependent cell
CC       migration via phosphorylation of BCAR1. May be involved both in adult
CC       synaptic function and plasticity and in brain development. Activates
CC       AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267'
CC       and 'Tyr-363' thereby promoting its recruitment to androgen-responsive
CC       enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates
CC       MCF2, thereby enhancing its activity as a guanine nucleotide exchange
CC       factor (GEF) toward Rho family proteins. Contributes to the control of
CC       AXL receptor levels. Confers metastatic properties on cancer cells and
CC       promotes tumor growth by negatively regulating tumor suppressor such as
CC       WWOX and positively regulating pro-survival factors such as AKT1 and
CC       AR. Phosphorylates WASP (PubMed:20110370).
CC       {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:11278436,
CC       ECO:0000269|PubMed:16247015, ECO:0000269|PubMed:16257963,
CC       ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:17038317,
CC       ECO:0000269|PubMed:18262180, ECO:0000269|PubMed:18435854,
CC       ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20110370,
CC       ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20383201}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963,
CC         ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068,
CC         ECO:0000269|PubMed:20333297};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:16257963,
CC         ECO:0000269|PubMed:18993068};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963,
CC         ECO:0000269|PubMed:20333297};
CC   -!- ACTIVITY REGULATION: Inhibited by AIM-100 (4-amino-5,6-biaryl-furo[2,3-
CC       d]pyrimidine), which suppresses activating phosphorylation at Tyr-284.
CC       Repressed by dasatinib. {ECO:0000269|PubMed:20383201,
CC       ECO:0000269|PubMed:20623637}.
CC   -!- SUBUNIT: Interacts with NEDD4 (via WW3 domain). NEDD4L and EGF promote
CC       association with NEDD4 (By similarity). Homodimer. Interacts with AR,
CC       CDC42, WWASL and WWOX. Interacts with CSPG4 (activated). Interacts with
CC       MERTK (activated); stimulates autophosphorylation. May interact
CC       (phosphorylated) with HSP90AB1; maintains kinase activity. Interacts
CC       with NPHP1. Interacts with SNX9 (via SH3 domain). Interacts with SRC
CC       (via SH2 and SH3 domain). Interacts with EGFR, and this interaction is
CC       dependent on EGF stimulation and kinase activity of EGFR. Interacts
CC       (via kinase domain) with AKT1. Part of a collagen stimulated complex
CC       involved in cell migration composed of CDC42, CRK, TNK2 and
CC       BCAR1/p130cas. Interacts with BCAR1/p130cas via SH3 domains. Forms
CC       complexes with GRB2 and numerous receptor tyrosine kinases (RTK)
CC       including LTK, AXL or PDGFRL, in which GRB2 promotes RTK recruitment by
CC       TNK2. {ECO:0000250, ECO:0000269|PubMed:10587647,
CC       ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:16257963,
CC       ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:17038317,
CC       ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:18477472,
CC       ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:19144635,
CC       ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20333297,
CC       ECO:0000269|PubMed:20979614, ECO:0000269|PubMed:21309750,
CC       ECO:0000269|PubMed:23686771, ECO:0000269|PubMed:8497321}.
CC   -!- INTERACTION:
CC       Q07912; P29972: AQP1; NbExp=3; IntAct=EBI-603457, EBI-745213;
CC       Q07912; P56945: BCAR1; NbExp=5; IntAct=EBI-603457, EBI-702093;
CC       Q07912; P60953-2: CDC42; NbExp=2; IntAct=EBI-603457, EBI-287394;
CC       Q07912; Q00610: CLTC; NbExp=3; IntAct=EBI-603457, EBI-354967;
CC       Q07912; P07902: GALT; NbExp=3; IntAct=EBI-603457, EBI-750827;
CC       Q07912; P08238: HSP90AB1; NbExp=3; IntAct=EBI-603457, EBI-352572;
CC       Q07912; Q9HC98: NEK6; NbExp=3; IntAct=EBI-603457, EBI-740364;
CC       Q07912; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-603457, EBI-945833;
CC       Q07912; O60880: SH2D1A; NbExp=3; IntAct=EBI-603457, EBI-6983382;
CC       Q07912; Q07912: TNK2; NbExp=2; IntAct=EBI-603457, EBI-603457;
CC       Q07912-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-11994780, EBI-3867333;
CC       Q07912-2; Q9BQC3: DPH2; NbExp=3; IntAct=EBI-11994780, EBI-10237931;
CC       Q07912-2; P07902: GALT; NbExp=3; IntAct=EBI-11994780, EBI-750827;
CC       Q07912-2; Q92569: PIK3R3; NbExp=3; IntAct=EBI-11994780, EBI-79893;
CC       Q07912-2; O60880: SH2D1A; NbExp=3; IntAct=EBI-11994780, EBI-6983382;
CC       Q07912-2; O14796: SH2D1B; NbExp=3; IntAct=EBI-11994780, EBI-3923013;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20333297,
CC       ECO:0000269|PubMed:20979614}. Nucleus {ECO:0000269|PubMed:14733946,
CC       ECO:0000269|PubMed:20333297}. Endosome {ECO:0000250|UniProtKB:O54967}.
CC       Cell junction, adherens junction {ECO:0000305}. Cytoplasmic vesicle
CC       membrane; Peripheral membrane protein; Cytoplasmic side
CC       {ECO:0000269|PubMed:16137687}. Cytoplasmic vesicle, clathrin-coated
CC       vesicle {ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:18262180}.
CC       Membrane, clathrin-coated pit {ECO:0000269|PubMed:21169560}. Cytoplasm,
CC       perinuclear region {ECO:0000269|PubMed:20110370}. Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:O54967}. Note=The Tyr-284 phosphorylated form is
CC       found both in the membrane and nucleus (By similarity). Co-localizes
CC       with EGFR on endosomes (PubMed:20333297). Nuclear translocation is
CC       CDC42-dependent (By similarity). Detected in long filamentous cytosolic
CC       structures where it co-localizes with CTPS1 (By similarity).
CC       {ECO:0000250|UniProtKB:O54967, ECO:0000269|PubMed:20333297}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q07912-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q07912-2; Sequence=VSP_008655, VSP_008656;
CC       Name=3;
CC         IsoId=Q07912-3; Sequence=VSP_037284, VSP_037285, VSP_037286;
CC   -!- TISSUE SPECIFICITY: The Tyr-284 phosphorylated form shows a significant
CC       increase in expression in breast cancers during the progressive stages
CC       i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS),
CC       invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM)
CC       stages. It also shows a significant increase in expression in prostate
CC       cancers during the progressive stages. {ECO:0000269|PubMed:16247015,
CC       ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20623637}.
CC   -!- DOMAIN: The EBD (EGFR-binding domain) domain is necessary for
CC       interaction with EGFR. {ECO:0000250}.
CC   -!- DOMAIN: The SAM-like domain is necessary for NEDD4-mediated
CC       ubiquitination. Promotes membrane localization and dimerization to
CC       allow for autophosphorylation. {ECO:0000269|PubMed:20979614}.
CC   -!- DOMAIN: The UBA domain binds both poly- and mono-ubiquitin.
CC       {ECO:0000269|PubMed:20979614}.
CC   -!- PTM: Autophosphorylation regulates kinase activity. Phosphorylation on
CC       Tyr-518 is required for interaction with SRC and is observed during
CC       association with clathrin-coated pits. {ECO:0000269|PubMed:15308621,
CC       ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297,
CC       ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614,
CC       ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750}.
CC   -!- PTM: Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be induced
CC       by EGF and is lysosome-dependent (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH08884.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305};
CC       Sequence=BAD18675.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13738; AAA53570.2; -; mRNA.
DR   EMBL; AK131539; BAD18675.1; ALT_INIT; mRNA.
DR   EMBL; AC124944; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008884; AAH08884.1; ALT_SEQ; mRNA.
DR   EMBL; BC028164; AAH28164.1; -; mRNA.
DR   CCDS; CCDS33927.1; -. [Q07912-3]
DR   CCDS; CCDS33928.1; -. [Q07912-1]
DR   PIR; S33596; S33596.
DR   RefSeq; NP_001010938.1; NM_001010938.1. [Q07912-3]
DR   RefSeq; NP_001294975.1; NM_001308046.1.
DR   RefSeq; NP_005772.3; NM_005781.4. [Q07912-1]
DR   PDB; 1CF4; NMR; -; B=448-489.
DR   PDB; 1U46; X-ray; 2.00 A; A/B=109-395.
DR   PDB; 1U4D; X-ray; 2.10 A; A/B=109-395.
DR   PDB; 1U54; X-ray; 2.80 A; A/B=109-395.
DR   PDB; 3EQP; X-ray; 2.30 A; A/B=117-392.
DR   PDB; 3EQR; X-ray; 2.00 A; A/B=117-392.
DR   PDB; 4EWH; X-ray; 2.50 A; A/B=117-391.
DR   PDB; 4HZR; X-ray; 1.31 A; A/B=115-389.
DR   PDB; 4HZS; X-ray; 3.23 A; A/B/C/D=115-453.
DR   PDB; 4ID7; X-ray; 3.00 A; A=117-389.
DR   PDB; 5ZXB; X-ray; 2.20 A; A/B=117-391.
DR   PDB; 6VQM; X-ray; 2.87 A; A/B=109-395.
DR   PDB; 7KP6; X-ray; 1.79 A; A/B=110-391.
DR   PDBsum; 1CF4; -.
DR   PDBsum; 1U46; -.
DR   PDBsum; 1U4D; -.
DR   PDBsum; 1U54; -.
DR   PDBsum; 3EQP; -.
DR   PDBsum; 3EQR; -.
DR   PDBsum; 4EWH; -.
DR   PDBsum; 4HZR; -.
DR   PDBsum; 4HZS; -.
DR   PDBsum; 4ID7; -.
DR   PDBsum; 5ZXB; -.
DR   PDBsum; 6VQM; -.
DR   PDBsum; 7KP6; -.
DR   AlphaFoldDB; Q07912; -.
DR   SMR; Q07912; -.
DR   BioGRID; 115485; 115.
DR   CORUM; Q07912; -.
DR   DIP; DIP-33858N; -.
DR   IntAct; Q07912; 71.
DR   MINT; Q07912; -.
DR   STRING; 9606.ENSP00000371341; -.
DR   BindingDB; Q07912; -.
DR   ChEMBL; CHEMBL4599; -.
DR   DrugBank; DB00171; ATP.
DR   DrugBank; DB04367; Debromohymenialdisine.
DR   DrugBank; DB11986; Entrectinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q07912; -.
DR   GuidetoPHARMACOLOGY; 2246; -.
DR   GlyGen; Q07912; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q07912; -.
DR   PhosphoSitePlus; Q07912; -.
DR   BioMuta; TNK2; -.
DR   DMDM; 229462980; -.
DR   CPTAC; CPTAC-1779; -.
DR   CPTAC; CPTAC-2789; -.
DR   EPD; Q07912; -.
DR   jPOST; Q07912; -.
DR   MassIVE; Q07912; -.
DR   MaxQB; Q07912; -.
DR   PaxDb; Q07912; -.
DR   PeptideAtlas; Q07912; -.
DR   PRIDE; Q07912; -.
DR   ProteomicsDB; 58556; -. [Q07912-1]
DR   ProteomicsDB; 58557; -. [Q07912-2]
DR   ProteomicsDB; 58558; -. [Q07912-3]
DR   Antibodypedia; 4095; 778 antibodies from 39 providers.
DR   CPTC; Q07912; 5 antibodies.
DR   DNASU; 10188; -.
DR   Ensembl; ENST00000333602.14; ENSP00000329425.6; ENSG00000061938.21. [Q07912-1]
DR   Ensembl; ENST00000439230.6; ENSP00000395588.1; ENSG00000061938.21. [Q07912-2]
DR   Ensembl; ENST00000671753.1; ENSP00000499858.1; ENSG00000061938.21. [Q07912-3]
DR   GeneID; 10188; -.
DR   KEGG; hsa:10188; -.
DR   UCSC; uc003fvt.2; human. [Q07912-1]
DR   CTD; 10188; -.
DR   DisGeNET; 10188; -.
DR   GeneCards; TNK2; -.
DR   HGNC; HGNC:19297; TNK2.
DR   HPA; ENSG00000061938; Tissue enhanced (brain).
DR   MalaCards; TNK2; -.
DR   MIM; 606994; gene.
DR   neXtProt; NX_Q07912; -.
DR   OpenTargets; ENSG00000061938; -.
DR   Orphanet; 391316; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression.
DR   PharmGKB; PA134909759; -.
DR   VEuPathDB; HostDB:ENSG00000061938; -.
DR   eggNOG; KOG0199; Eukaryota.
DR   GeneTree; ENSGT00940000160853; -.
DR   HOGENOM; CLU_000288_7_39_1; -.
DR   InParanoid; Q07912; -.
DR   OrthoDB; 1008736at2759; -.
DR   PhylomeDB; Q07912; -.
DR   TreeFam; TF316643; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q07912; -.
DR   SignaLink; Q07912; -.
DR   SIGNOR; Q07912; -.
DR   BioGRID-ORCS; 10188; 10 hits in 1111 CRISPR screens.
DR   ChiTaRS; TNK2; human.
DR   EvolutionaryTrace; Q07912; -.
DR   GeneWiki; TNK2; -.
DR   GenomeRNAi; 10188; -.
DR   Pharos; Q07912; Tclin.
DR   PRO; PR:Q07912; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q07912; protein.
DR   Bgee; ENSG00000061938; Expressed in right hemisphere of cerebellum and 190 other tissues.
DR   ExpressionAtlas; Q07912; baseline and differential.
DR   Genevisible; Q07912; HS.
DR   GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB.
DR   GO; GO:0097268; C:cytoophidium; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0070436; C:Grb2-EGFR complex; IDA:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0005095; F:GTPase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0050699; F:WW domain binding; ISS:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; IDA:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   DisProt; DP01772; -.
DR   Gene3D; 4.10.680.10; -; 1.
DR   IDEAL; IID00276; -.
DR   InterPro; IPR030220; Ack1.
DR   InterPro; IPR015116; Cdc42-bd-like.
DR   InterPro; IPR037085; Cdc42-bd-like_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR021619; Mig-6.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   PANTHER; PTHR14254:SF6; PTHR14254:SF6; 1.
DR   Pfam; PF09027; GTPase_binding; 1.
DR   Pfam; PF11555; Inhibitor_Mig-6; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Coated pit; Cytoplasm; Cytoplasmic vesicle; Endocytosis;
KW   Endosome; Kinase; Magnesium; Membrane; Metal-binding; Methylation;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN           1..1038
FT                   /note="Activated CDC42 kinase 1"
FT                   /id="PRO_0000088058"
FT   DOMAIN          126..385
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          388..448
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          454..466
FT                   /note="CRIB"
FT   DOMAIN          958..996
FT                   /note="UBA"
FT   REGION          1..110
FT                   /note="SAM-like domain"
FT   REGION          90..114
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          497..535
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          623..652
FT                   /note="Required for interaction with SRC"
FT                   /evidence="ECO:0000269|PubMed:21309750"
FT   REGION          632..635
FT                   /note="Required for interaction with NEDD4"
FT                   /evidence="ECO:0000250"
FT   REGION          659..702
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          718..840
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          733..876
FT                   /note="EBD domain"
FT                   /evidence="ECO:0000250"
FT   REGION          917..957
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        724..756
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        772..805
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        806..827
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        252
FT                   /note="Proton acceptor"
FT   BINDING         132..140
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         158
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         284
FT                   /note="Phosphotyrosine; by SRC and autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15308621,
FT                   ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297,
FT                   ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614,
FT                   ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         518
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:21169560"
FT   MOD_RES         724
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         827
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:21169560"
FT   MOD_RES         839
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:O54967"
FT   MOD_RES         859
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:21169560"
FT   MOD_RES         872
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:21169560"
FT   MOD_RES         881
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   VAR_SEQ         1
FT                   /note="M -> MGERSAYQRLAGGEEGPQRLGGGRM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037284"
FT   VAR_SEQ         485..528
FT                   /note="LYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPL -> CPFS
FT                   AFSPGHPPAETCGQVLWTGRREACASDPRLHPVSSRTKGL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008655"
FT   VAR_SEQ         514
FT                   /note="K -> KREPPPRPPQPAFFTQ (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037285"
FT   VAR_SEQ         529..1038
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008656"
FT   VAR_SEQ         965..994
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037286"
FT   VARIANT         34
FT                   /note="R -> L (in a lung adenocarcinoma sample; somatic
FT                   mutation; increased autophosphorylation at Y-284; increased
FT                   function in phosphorylation of peptide substrates; no
FT                   effect on subcellular localization to perinuclear region)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:20110370"
FT                   /id="VAR_032792"
FT   VARIANT         71
FT                   /note="K -> R (in dbSNP:rs56036945)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032793"
FT   VARIANT         99
FT                   /note="R -> Q (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation; increased autophosphorylation at Y-284;
FT                   increased function in phosphorylation of peptide substrates
FT                   and WASP; no effect on subcellular localization to
FT                   perinuclear region; dbSNP:rs113498671)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:20110370"
FT                   /id="VAR_032794"
FT   VARIANT         99
FT                   /note="R -> W (in dbSNP:rs3747673)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032795"
FT   VARIANT         152
FT                   /note="T -> M (in dbSNP:rs56161912)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032796"
FT   VARIANT         346
FT                   /note="E -> K (in an ovarian endometrioid cancer sample;
FT                   somatic mutation; undergoes autoactivation and causes
FT                   phosphorylation on Y-284 leading to activation of AKT1;
FT                   increased autophosphorylation at Y-284; increased function
FT                   in phosphorylation of peptide substrates and WASP; no
FT                   effect on catalytic activity itself as the purified kinase
FT                   domain has activity in vitro comparable to wild-type
FT                   protein; no effect on subcellular localization to
FT                   perinuclear region; dbSNP:rs970946035)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:20110370, ECO:0000269|PubMed:20333297"
FT                   /id="VAR_032797"
FT   VARIANT         409
FT                   /note="M -> I (in a gastric adenocarcinoma sample; somatic
FT                   mutation; increased autophosphorylation at Y-284; increased
FT                   function in phosphorylation of peptide substrates and WASP;
FT                   no effect on subcellular localization to perinuclear
FT                   region)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:20110370"
FT                   /id="VAR_032798"
FT   VARIANT         507
FT                   /note="P -> S (in dbSNP:rs35759128)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032799"
FT   VARIANT         638
FT                   /note="V -> M (found in patients with childhood-onset
FT                   epilepsy; unknown pathological significance; loss of
FT                   interaction with NEDD4 and NEDD4L; increased protein
FT                   abundance; dbSNP:rs201407161)"
FT                   /evidence="ECO:0000269|PubMed:23686771"
FT                   /id="VAR_076966"
FT   VARIANT         725
FT                   /note="P -> L (in dbSNP:rs56260729)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032800"
FT   VARIANT         748
FT                   /note="R -> Q (in dbSNP:rs57872314)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032801"
FT   VARIANT         802
FT                   /note="P -> L (in dbSNP:rs3749333)"
FT                   /id="VAR_057115"
FT   VARIANT         1038
FT                   /note="R -> H (in dbSNP:rs13433937)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032802"
FT   MUTAGEN         120
FT                   /note="L->Q: No effect on autophosphorylation at Y-284."
FT                   /evidence="ECO:0000269|PubMed:20110370"
FT   MUTAGEN         158
FT                   /note="K->R: Loss of autophosphorylation at Y-284."
FT                   /evidence="ECO:0000269|PubMed:16288044,
FT                   ECO:0000269|PubMed:20110370"
FT   MUTAGEN         197
FT                   /note="L->Q: No effect on autophosphorylation at Y-284."
FT                   /evidence="ECO:0000269|PubMed:20110370"
FT   MUTAGEN         365
FT                   /note="V->R: Increased autophosphorylation at Y-284."
FT                   /evidence="ECO:0000269|PubMed:20110370"
FT   MUTAGEN         487
FT                   /note="L->F: Constantly active kinase."
FT                   /evidence="ECO:0000269|PubMed:16288044"
FT   CONFLICT        138
FT                   /note="G -> V (in Ref. 4; AAH08884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        304..352
FT                   /note="TRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPR ->
FT                   PPWRDISASSSTQFPHAVPCFPTSLLAKLLLRHSVPASSREIKLVSILC (in Ref.
FT                   4; AAH08884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        353..1038
FT                   /note="Missing (in Ref. 4; AAH08884)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        586
FT                   /note="A -> P (in Ref. 1; AAA53570)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        722
FT                   /note="Missing (in Ref. 1; AAA53570)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        838..840
FT                   /note="PRA -> AG (in Ref. 1; AAA53570)"
FT                   /evidence="ECO:0000305"
FT   STRAND          118..120
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   HELIX           123..125
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          126..133
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          140..146
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:3EQP"
FT   STRAND          152..159
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   TURN            164..166
FT                   /evidence="ECO:0007829|PDB:3EQR"
FT   HELIX           171..181
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          192..196
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          198..200
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          202..206
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           213..219
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           221..223
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           226..245
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           255..257
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          258..262
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          265..268
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           273..276
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   STRAND          283..285
FT                   /evidence="ECO:0007829|PDB:1U46"
FT   HELIX           288..290
FT                   /evidence="ECO:0007829|PDB:3EQP"
FT   HELIX           294..296
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           299..304
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          306..308
FT                   /evidence="ECO:0007829|PDB:1U46"
FT   HELIX           309..324
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   TURN            325..327
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   TURN            330..333
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           336..344
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           358..367
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           372..374
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   HELIX           378..387
FT                   /evidence="ECO:0007829|PDB:4HZR"
FT   STRAND          392..394
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   STRAND          402..404
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   STRAND          412..417
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   STRAND          419..421
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   STRAND          423..432
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   STRAND          435..439
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   HELIX           440..443
FT                   /evidence="ECO:0007829|PDB:4HZS"
FT   STRAND          449..451
FT                   /evidence="ECO:0007829|PDB:1CF4"
FT   TURN            484..486
FT                   /evidence="ECO:0007829|PDB:1CF4"
SQ   SEQUENCE   1038 AA;  114569 MW;  74A1980665BC3E6B CRC64;
     MQPEEGTGWL LELLSEVQLQ QYFLRLRDDL NVTRLSHFEY VKNEDLEKIG MGRPGQRRLW
     EAVKRRKALC KRKSWMSKVF SGKRLEAEFP PHHSQSTFRK TSPAPGGPAG EGPLQSLTCL
     IGEKDLRLLE KLGDGSFGVV RRGEWDAPSG KTVSVAVKCL KPDVLSQPEA MDDFIREVNA
     MHSLDHRNLI RLYGVVLTPP MKMVTELAPL GSLLDRLRKH QGHFLLGTLS RYAVQVAEGM
     GYLESKRFIH RDLAARNLLL ATRDLVKIGD FGLMRALPQN DDHYVMQEHR KVPFAWCAPE
     SLKTRTFSHA SDTWMFGVTL WEMFTYGQEP WIGLNGSQIL HKIDKEGERL PRPEDCPQDI
     YNVMVQCWAH KPEDRPTFVA LRDFLLEAQP TDMRALQDFE EPDKLHIQMN DVITVIEGRA
     ENYWWRGQNT RTLCVGPFPR NVVTSVAGLS AQDISQPLQN SFIHTGHGDS DPRHCWGFPD
     RIDELYLGNP MDPPDLLSVE LSTSRPPQHL GGVKKPTYDP VSEDQDPLSS DFKRLGLRKP
     GLPRGLWLAK PSARVPGTKA SRGSGAEVTL IDFGEEPVVP ALRPCAPSLA QLAMDACSLL
     DETPPQSPTR ALPRPLHPTP VVDWDARPLP PPPAYDDVAQ DEDDFEICSI NSTLVGAGVP
     AGPSQGQTNY AFVPEQARPP PPLEDNLFLP PQGGGKPPSS AQTAEIFQAL QQECMRQLQA
     PAGSPAPSPS PGGDDKPQVP PRVPIPPRPT RPHVQLSPAP PGEEETSQWP GPASPPRVPP
     REPLSPQGSR TPSPLVPPGS SPLPPRLSSS PGKTMPTTQS FASDPKYATP QVIQAPGPRA
     GPCILPIVRD GKKVSSTHYY LLPERPSYLE RYQRFLREAQ SPEEPTPLPV PLLLPPPSTP
     APAAPTATVR PMPQAALDPK ANFSTNNSNP GARPPPPRAT ARLPQRGCPG DGPEAGRPAD
     KIQMAMVHGV TTEECQAALQ CHGWSVQRAA QYLKVEQLFG LGLRPRGECH KVLEMFDWNL
     EQAGCHLLGS WGPAHHKR
//
